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ARTICLE
Gut bacterial tyrosine decarboxylases restrict levels
of levodopa in the treatment of Parkinson’s disease
Sebastiaan P. van Kessel1, Alexandra K. Frye1, Ahmed O. El-Gendy 1,4, Maria Castejon1, Ali Keshavarzian2,
Gertjan van Dijk3 & Sahar El Aidy 1
Human gut microbiota senses its environment and responds by releasing metabolites, some
of which are key regulators of human health and disease. In this study, we characterize gut-
associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine dec-
arboxylases. Bacterial tyrosine decarboxylases efﬁciently convert levodopa to dopamine, even
in the presence of tyrosine, a competitive substrate, or inhibitors of human decarboxylase. In
situ levels of levodopa are compromised by high abundance of gut bacterial tyrosine dec-
arboxylase in patients with Parkinson’s disease. Finally, the higher relative abundance of
bacterial tyrosine decarboxylases at the site of levodopa absorption, proximal small intestine,
had a signiﬁcant impact on levels of levodopa in the plasma of rats. Our results highlight the
role of microbial metabolism in drug availability, and speciﬁcally, that abundance of bacterial
tyrosine decarboxylase in the proximal small intestine can explain the increased dosage
regimen of levodopa treatment in Parkinson’s disease patients.
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Gut bacteria interfere with effectiveness of drug treatment.The complex bacterial communities inhabiting themammalian gut have a signiﬁcant impact on the health of
their host1. Numerous reports indicate that intestinal microbiota,
and in particular its metabolic products, have a crucial effect on
various health and diseased states. Host immune system and
brain development, metabolism, behavior, stress and pain
response all have been reported to be associated with microbiota
disturbances2–6. In addition, it is becoming increasingly clear that
gut microbiota can interfere with the modulation of drug
efﬁcacy7,8.
Parkinson’s disease (PD), the second most common neuro-
degenerative disorder, affecting 1% of the global population
over the age of 60, and has recently been correlated with
alterations in microbial gut composition9–11. The primary
treatment of PD is levodopa (L-3,4-dihydroxyphenylalanine or
L-DOPA) in combination of an aromatic amino acid dec-
arboxylase inhibitor (primarily carbidopa)12. However, the
bioavailability of levodopa/ decarboxylase inhibitor, required to
ensure sufﬁcient amounts of dopamine will reach the brain13,
varies signiﬁcantly among PD patients. Because of this, levo-
dopa/ decarboxylase inhibitor is ineffective in a subset of
patients, and its efﬁcacy decreases over time of treatment,
necessitating more frequent drug doses, ranging from 3 to 8-10
tablets/day with higher risk of dyskinesia and other side
effects14. A major challenge in the clinic is an early diagnosis of
motor response ﬂuctuation (timing of movement‐related
potentials) and decreased levodopa/ decarboxylase inhibitor
efﬁcacy to determine optimal dosage for individual patients and
during disease progression. What remains to be clariﬁed is
whether inter-individual variations in gut microbiota compo-
sition and functionality play a causative role in motor response
ﬂuctuation in PD patients requiring higher daily levodopa/
decarboxylase inhibitor treatment dosage regimen.
In fact, it had been shown that large intestinal microbiota could
mainly dehydroxylate levodopa as detected in urine and cecal
content of conventional rats15. However, these results do not
explain a possible role of gut microbiota in the increased dosage
regimen of levodopa/decarboxylase inhibitor treatment in PD
patients because the primary site of levodopa absorption is the
proximal small intestine (jejunum)16.
Several amino acid decarboxylases have been identiﬁed in
bacteria. Tyrosine decarboxylase (TDC) genes (tdc) have
especially been encoded in the genome of several bacterial
species in the genera Lactobacillus and Enterococcus17,18.
Though TDC is named for its capacity to decarboxylate L-
tyrosine into tyramine, it might also have the ability to dec-
arboxylate levodopa to produce dopamine due to the high
similarity of the chemical structures of these substrates. This
implies that TDC activity of the gut microbiota might interfere
with levodopa/decarboxylase inhibitor availability, thus the
treatment of PD patients.
The aim of the present study is to parse out the effect of
levodopa metabolizing bacteria, particularly in the jejunum,
where levodopa is absorbed. Initially, we established TDC present
in small intestinal bacteria efﬁciently converted levodopa to
dopamine, conﬁrming their capacity to inﬂuence the in situ levels
of the primary treatment of PD patients. We show that higher
relative abundance of bacterial tdc gene in stool samples of PD
patients positively correlates with higher daily levodopa/carbi-
dopa dosage requirement and duration of disease. We
further conﬁrm our ﬁndings in rats orally administered levodopa/
carbidopa, illustrating that levodopa levels in plasma
negatively correlate with the abundance of bacterial tdc gene in
the jejunum.
Results
Upper small intestinal bacteria convert levodopa to dopamine.
To determine whether jejunal microbiota maintain the ability to
metabolize levodopa, luminal samples from the entire jejunum of
wild-type Groningen rats housed in different cages were incu-
bated in vitro with levodopa and analyzed by High-Performance
Liquid Chromatography with Electrochemical Detection (HPLC-
ED). Chromatograms revealed that levodopa decarboxylation to
dopamine coincide with the conversion of tyrosine to tyramine
(Fig. 1a). Ranking the chromatograms from high to low dec-
arboxylation of levodopa and tyrosine, shows that only when
tyrosine is decarboxylated, dopamine is produced (Fig. 1b). No
other metabolites were detected in the treated samples, except of
few unknown peaks, which were also present in the control
samples, thus are not products of bacterial metabolism of levo-
dopa. In addition, no dopamine production was observed in
control samples (Supplementary Fig. 1). Of note, no basal levels
of levodopa were detected in the measured samples by HPLC.
Taken together, the results suggest that bacterial TDC is involved
in levodopa conversion into dopamine, which may, in turn,
interfere with levodopa uptake in the proximal small intestine.
Levodopa decarboxylation by bacterial TDC. The coinciding
tyrosine and levodopa decarboxylation observed in the luminal
content of jejunum was the basis of our hypothesis that TDC is
the enzyme involved in both conversions. Species of the genera
Lactobacillus and Enterococcus have been reported to harbor this
enzyme17,19. To identify whether the genome of other (small
intestinal) gut bacteria also encode tdc, the TDC protein sequence
(EOT87933) from Enterococcus faecalis v583 was used as a query
to search the US National Institutes of Health Human Micro-
biome Project (HMP) protein database. This analysis exclusively
identiﬁed TDC proteins in species belonging to the bacilli class,
including more than 50 Enterococcus strains (mainly E. faecium
and E. faecalis) and several Lactobacillus and Staphylococcus
species (Supplementary Fig. 2a). Next, we aligned the genome of
E. faecalis v583 with two gut bacterial isolates, E. faecium W54,
and L. brevis W63, illustrating the conservation of the tdc-operon
among these species (Fig. 2a). Intriguingly, analysis of E. faecium
genomes revealed that this species encodes a second, paralogous
tdc gene (PTDCEFM) that did not align with the conserved tdc-
operon and was absent from the other species (Fig. 2a, Supple-
mentary Figs. 2a and 6).
To support our in silico data, a comprehensive screening of E.
faecalis v583, E. faecium W54, and L. brevis W63 and 77
additional clinical and human isolates of Enterococcus, including
clinical isolates and strains from healthy subjects, was performed.
All enterococcal isolates and L. brevis were able to convert
tyrosine and levodopa into tyramine and dopamine, respectively
(Fig. 2b–d, Supplementary Table 1). Notably, our HPLC-ED
analysis revealed considerable variability among the tested strains
with regard to their efﬁciency to decarboxylate levodopa. E.
faecium and E. faecalis were drastically more efﬁcient at
converting levodopa to dopamine, compared to L. brevis.
Growing L. brevis in different growth media did not change the
levodopa decarboxylation efﬁcacy (Supplementary Fig. 2b, c). To
eliminate the possibility that other bacterial amino acid
decarboxylases are involved in levodopa conversion observed in
the jejunal content we expanded our screening to include live
bacterial species harboring PLP-dependent amino acid decarbox-
ylases previously identiﬁed by Williams et al.20. None of the
tested bacterial strains encoding different amino acid decarbox-
ylases could decarboxylate levodopa (Supplementary Fig. 2d–g,
Supplementary Table 2).
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To verify that the TDC is solely responsible for levodopa
decarboxylation in Enterococcus, wild-type E. faecalis v583
(EFSWT) was compared with a mutant strain (EFSΔTDC)17.
Overnight incubation of EFSWT and EFSΔTDC bacterial cells with
levodopa resulted in production of dopamine in the supernatant
of EFSWT but not EFSΔTDC (Fig. 2e), conﬁrming the pivotal role
of this gene in this conversion. Collectively, results show that
TDC is encoded on genomes of gut bacterial species known to
dominate the proximal small intestine and that this enzyme is
exclusively responsible for converting levodopa to dopamine by
these bacteria, although the efﬁciency of that conversion displays
considerable species-dependent variability.
Tyrosine abundance does not prevent levodopa decarboxylation.
To test whether the availability of the primary substrate for
bacterial TDC (i.e., tyrosine) could inhibit the uptake and dec-
arboxylation of levodopa, the growth, metabolites, and pH that
was previously shown to affect the expression of tdc17, of E.
faecium W54 and E. faecalis v583 were analyzed over time. A
volume of 100 µM levodopa was added to the bacterial cultures,
whereas ~500 µM tyrosine was present in the growth media,
which corresponds to the levels of tyrosine found in the jeju-
num21. Remarkably, levodopa and tyrosine were converted
simultaneously, even in the presence of these excess levels of
tyrosine (1:5 levodopa to tyrosine), albeit at a slower conversion
rate for levodopa (Fig. 3a, b). Notably, the decarboxylation
reaction appeared operational throughout the exponential phase
of growth for E. faecalis, whereas it is only observed in E. faecium
when this bacterium entered the stationary phase of growth,
suggesting differential regulation of the tdc gene expression in
these species.
To further characterize the substrate speciﬁcity and kinetic
parameters of the bacterial TDCs, tdc genes from E. faecalis v583
(TDCEFS) and E. faecium W54 (TDCEFM and PTDCEFM) were
expressed in Escherichia coli BL21 (DE3) and then puriﬁed.
Michaelis–Menten kinetics indicated each of the studied enzymes
had a signiﬁcantly higher afﬁnity (Km) (Fig. 3c–i) and catalytic
efﬁciency (Kcat/Km) for tyrosine than for levodopa (Table 1).
Despite the differential substrate afﬁnity, our ﬁndings illustrate
that high levels of tyrosine do not prevent the decarboxylation of
levodopa in batch culture.
Carbidopa does not inhibit bacterial decarboxylases. To assess
the extent to which human DOPA decarboxylase inhibitors could
affect bacterial decarboxylases, three human DOPA decarboxylase
inhibitors (carbidopa, benserazide, and methyldopa) were tested
on puriﬁed bacterial TDCs and on the corresponding bacterial
batch cultures. Comparison of the inhibitory constants (KiTDC/
KiDDC) demonstrates carbidopa to be a 1.4–1.9 × 104 times more
potent inhibitor of human DOPA decarboxylase than bacterial
TDCs (Fig. 4a, Supplementary Fig. 3; Supplementary Table 3).
This is best illustrated by the observation that levodopa
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Fig. 1 Bacteria in jejunal content decarboxylate levodopa to dopamine coinciding with their production of tyramine ex vivo. a Decarboxylation reaction for
tyrosine and levodopa. b From left to right coinciding bacterial conversion of tyrosine (TYR) to tyramine (TYRM) and 1 mM of supplemented levodopa (LD)
to dopamine (DA) during 24 h of incubation of jejunal content. The jejunal contents are from four different rats ranked form left to right based on the
decarboxylation levels of tyrosine and levodopa, showing that tyrosine decarboxylation is coinciding with levodopa decarboxylation
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conversion by E. faecium W54 and E. faecalis v583 batch cultures
(OD600= ~2.0) was unaffected by co-incubation with carbidopa
(equimolar or 4-fold carbidopa relative to levodopa) (Fig. 4b, c,
Supplementary Fig. 4a). Analogously, benserazide and methyl-
dopa did not inhibit the levodopa decarboxylation activity in E.
faecalis or E. faecium (Supplementary Fig. 4b, c).
These ﬁndings demonstrate the commonly applied inhibitors
of human DOPA decarboxylase in levodopa combination therapy
do not inhibit bacterial TDC dependent levodopa conversion,
implying levodopa/carbidopa (levodopa) combination therapy for
PD patients would not affect the efﬁcacy of levodopa in situ by
small intestinal bacteria.
PD dosage regimen correlates with tdc gene abundance. To
determine whether the increased dosage regimen of levodopa
treatment in PD patients could be attributed to the abundance of
tdc genes in the gut microbiota, fecal samples were collected from
male and female PD patients (Supplementary Table 4) on dif-
ferent doses of levodopa/carbidopa treatment (ranging from 300
up to 1100 mg levodopa per day). tdc gene-speciﬁc primers were
0 hrs
02462 02463 02464 02465 02466 02467
























0029600295 00297 00298 00299 0030000291
EF3012 EF3013 EF3014 EF3015EF3011EF3010EF3009EF3008EF3007EF3006
01562 01563 01566 01566 01567 01568 01569 01570 01571 01572 01573
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Time (min)
Time (min)
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.02.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Time (min)
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Time (min)





































Fig. 2 Gut bacteria harboring tyrosine decarboxylases are responsible for levodopa decarboxylation. a Aligned genomes of E. faecium, E. faecalis, and L.
brevis. The conserved tdc-operon is depicted with tdc gene in orange. Overnight cultures of b E. faecalis v583, c E. faecium W54, and d L. brevis W63
incubated anaerobically at 37 °C with 100 µM of levodopa (LD). e Overnight cultures of EFSWT and EFSΔTDC incubated anaerobically at 37 °C with 100 μM
levodopa (black line) compared to control (gray line) where no levodopa was added. Curves represent one example of three biological replicates
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Fig. 3 Enterococci decarboxylate levodopa in presence of tyrosine despite higher afﬁnity for tyrosine in vitro. Growth curve (gray circle, right Y-axis) of E.
faecium W54 (a) and E. faecalis (b) plotted together with levodopa (open square), dopamine (closed square), tyrosine (open triangle), and tyramine
(closed triangle) levels (left Y-axis). Concentrations of product and substrate were normalized to the initial levels of the corresponding substrate (100 µM
supplemented levodopa and ~500 µM tyrosine present in the medium). pH of the culture is indicated over time as a red line. c Substrate afﬁnity (Km) for
levodopa and tyrosine for puriﬁed tyrosine decarboxylases from E. faecalis v583 (TDCEFS), E. faecium W54 (TDCEFM, PTDCEFM). d–i Michaelis–Menten
kinetic curves for levodopa and tyrosine as substrate for TDCEFS (d, e), TDCEFM (f, g), and PTDCEFM (h, i). Reactions were performed in triplicate using
levodopa concentrations ranging from 0.5 to 12.5 mM and tyrosine concentrations ranging from 0.25 to 2.5 mM. The enzyme kinetic parameters were
calculated using nonlinear Michaelis–Menten regression model. Error bars represent the SEM and signiﬁcance was tested using 2-way-Anova, Fisher LSD
test, (*p < 0.02; **p < 0.01; ****<0.0001)
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used to quantify its relative abundance within the gut microbiota
by qPCR and results were normalized to 16S rRNA gene to
correct for difference in total bacterial counts among the stool
samples (Supplementary Fig. 5). Remarkably, Pearson r
correlation analyses showed a strong positive correlation (r=
0.66, R2= 0.44, p value= 0.037) between bacterial tdc gene
relative abundance and levodopa/carbidopa treatment dose
(Fig. 5a), as well as with the duration of disease (Fig. 5b, Sup-
plementary Table 5). Collectively, the selective prevalence of tdc
encoding genes in the genomes of signature microbes of the small
intestine microbiota supports the notion that the results obtained
from fecal samples are a valid representation of tdc gene abun-
dance in the small intestinal microbiota. Moreover, the signiﬁcant
correlation of the relative tdc abundance in the fecal microbiota
and the required levodopa/carbidopa dosage strongly supports a
role for bacterial TDC in levodopa/carbidopa efﬁcacy.
At this stage, it is not demonstrated whether the relative
abundance of tdc in fecal samples reﬂects its abundance in the
proximal small intestine. This is of particular importance because
levodopa is absorbed in the proximal small intestine, and
reduction in its bioavailability by bacterial TDC activity in the
context of PD patients’ medication regimens would only be
relevant in that intestinal region.
Higher tdc gene abundance restricts levodopa level in plasma.
To further consolidate the concept that tdc gene abundance in
proximal small intestinal microbiota affects peripheral levels of
levodopa/carbidopa in blood and dopamine: levodopa/carbidopa
ratio in the jejunal luminal content, male wild-type Groningen
rats (n= 18) rats were orally administered 15 mg levodopa/3.75
mg carbidopa per kg of body weight and sacriﬁced after 15 min
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Fig. 4 Human DOPA decarboxylase inhibitor, carbidopa, does not inhibit bacterial tyrosine decarboxylases. a Inhibitory constants (Ki) of bacterial
decarboxylases (black) and human DOPA decarboxylase (gray), with fold-difference between bacterial and human decarboxylase displayed on top of the
bars. Quantitative comparison of dopamine (DA) production by E. faecium W54, b and E. faecalis v583, c at stationary phase after 15 min, with
representative HPLC-ED curve. Bacterial cultures (n= 3) were incubated with 100 µM levodopa (LD) or a 4:1 mixture (in weight) of levodopa and
carbidopa (CD) (100 µM levodopa and 21.7 µM carbidopa). Error bars represent SEM (a) or SD (b, c) and signiﬁcance was tested using a parametric
unpaired T-test
Table 1 Michaelis–Menten kinetic parameters
Levodopa pH 5.0 pH 5.0 pH 4.5 pH 7.4
TDCEFS TDCEFM PTDCEFM DDC
[E] (nM) 10 10 10 10
Km (mM) 3 ± 0.4 7.2 ± 0.8 0.4 ± 0.1 0.1 ± 0.01
Vmax (µM/min) 35.3 ± 1.4 25.5 ± 1.3 3.4 ± 0.2 1.4 ± 0.03
Kcat (min−1) 3531 ± 137 2549 ± 133 342.4 ± 21 136.9 ± 3
Kcat/Km (min
−1/mM−1)
1160 352 764 1567
R2 0.978 0.99 0.621 0.962
Tyrosine pH 5.0 pH 5.0 pH 4.5
TDCEFS TDCEFM PTDCEFM
[E] (nM) 10 10 10
Km (mM) 0.6 ± 0.1 1.5 ± 0.3 0.2 ± 0.05
Vmax (µM/min) 69.6 ± 2.9 22 ± 2.5 4.4 ± 0.2
Kcat (min−1) 6963 ±
288




R2 0.928 0.902 0.589
Enzyme kinetic parameters were determined by Michaelis–Menten nonlinear regression model
for levodopa and tyrosine as substrates. ± indicates the standard error
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levels of levodopa/carbidopa and its metabolite dopamine were
measured by HPLC-ED, while relative abundance of the tdc gene
within the small intestinal microbiota was quantiﬁed by gene-
speciﬁc qPCR (Supplementary Fig. 5). Strikingly, Pearson r cor-
relation analyses showed that the ratio between dopamine and
levodopa/carbidopa levels in the proximal jejunal content posi-
tively correlated with tdc gene abundance (r= 0.78, R2= 0.61,
P value= 0.0001), whereas the levodopa/carbidopa concentration
in the proximal jejunal content negatively correlated with the
abundance of the tdc gene (r=−0.68, R2= 0.46, P value= 0.021)
(Fig. 6a). Moreover, plasma levels of levodopa/carbidopa dis-
played a strong negative correlation (r=−0.57, R2= 0.33,
P value= 0.017) with the relative abundance of the tdc gene
(Fig. 6b). No basal levels of levodopa were detected in the mea-
sured samples by HPLC-ED.
To further support this correlation, plasma levels of levodopa/
carbidopa from rats treated with EFSWT (n= 10) or EFSΔTDC
(n= 10) cells were determined after oral administration with
levodopa/carbidopa mixture (4:1). Rats treated with EFSWT
showed signiﬁcant lower levels (P value < 0.01) of levodopa/
carbidopa in their plasma compared to rats treated with EFSΔTDC
(Fig. 6c). Collectively, these ﬁndings clearly show that levodopa/
carbidopa uptake by the host is compromised by higher
abundance of gut bacteria encoding for tdc genes in the upper
region of the small intestine.
Discussion
Our observation that the jejunal microbiota are able to convert
levodopa to dopamine (Fig. 1) was the basis of investigating the
role of levodopa metabolizing bacteria in the context of the dis-
parity in increased dosage regimen of levodopa/carbidopa treat-
ment in a subset of PD patients (Fig. 5) and the accompanying
adverse side effects23. This study identiﬁes a signiﬁcant factor to
explain the motor response (timing of movement‐related poten-
tials) ﬂuctuations observed in PD patients requiring frequent
levodopa/decarboxylase inhibitor administration.
Our primary outcome is that levodopa decarboxylation by
small intestinal bacteria, in particular, members of bacilli,
including the genera Enterococcus and Lactobacillus, which were
previously identiﬁed as the predominant residents of the small
intestine24,25, would drastically reduce the levels of levodopa/
decarboxylase inhibitor in the body, and thereby contribute to the
observed higher dosages required in a subset of PD patients.
Previously, reduced levodopa availability has been associated with
Helicobacter pylori positive PD patients, which was explained by
the observation that H. pylori could bind levodopa in vitro via
surface adhesins8. However, this explanation is valid only for a
small population of the PD patients, who suffer from stomach
ulcers and thus have high abundance of H. pylori.
The impaired intestinal motility frequently observed in PD
patients26 could also result from altered levels of dopamine, the
conversion product of bacterial tdc metabolism of levodopa27 but
has been also associated with small intestinal bacterial over-
growth28, and worsening of motor response ﬂuctuations thus
requiring higher dosage frequency of levodopa/decarboxylase
inhibitor treatment29. Moreover, the decreasing efﬁcacy of levo-
dopa treatment observed in PD patients might be explained by
the overgrowth of small intestinal bacteria that metabolize levo-
dopa resulting from proton pump inhibitors30–32, for treatment
of gastrointestinal symptoms. In particular, Enterococcus has been
reported to dominate in proton pump inhibitors’ induced small
intestinal bacterial overgrowth33. Altogether, these factors will
enhance a state of small intestinal bacterial overgrowth, and
perpetuating a vicious circle leading to increased levodopa/dec-
arboxylase inhibitor dosage requirement in a subset of PD
patients (Fig. 7). Finally, it is likely that prolonged levodopa/
decarboxylase inhibitor administration favors growth of tdc
expressing bacteria in the proximal small intestine, resulting in
higher levels of tdc further lowering the efﬁcacy of levodopa. In
fact, it has been shown that the ﬁtness of E. faecalis v583 in low
pH depends on the tdc-operon17, indicating long-term exposure
to levodopa could contribute to selection for overgrowth of tdc
encoding bacteria in vivo as supported by the positive correlation
with tdc gene abundance observed in human stool samples
(Fig. 5b). This would explain the ﬂuctuating motor response and
subsequent increased levodopa/decarboxylase inhibitor dosage
regimen thus severity of its adverse effects, such as dyskinesia
during prolonged disease treatment34.
While our further investigation into the kinetics of both bac-
terial and human decarboxylases support the effectiveness of
carbidopa to inhibit the human DOPA decarboxylase, it also
shows that the same drug fails to inhibit levodopa decarboxyla-
tion by bacterial TDC, probably due to the presence of an extra
hydroxyl group on the benzene ring of carbidopa (Fig. 4, Sup-
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Fig. 5 Tyrosine decarboxylase gene abundance correlates with daily levodopa dose and disease duration in fecal samples of Parkinson’s disease patients.
a Scatter plot of tdc gene abundance measured by qPCR in fecal samples of PD patients (n= 10) versus daily levodopa/carbidopa dosage ﬁtted with linear
regression model. b Scatter plot of tdc gene abundance from the same samples versus disease duration ﬁtted with a linear regression model. Pearson’s r
analysis was used to determine signiﬁcant correlations between tyrosine decarboxylase gene abundance and dosage (r= 0.66, R2= 0.44, P value=
0.037) or disease duration (r= 0.82, R2= 0.68, P value= 0.003)
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the bacterial cell. This suggests a better equilibration of levodopa
treatment between patients could potentially be achieved by co-
administration of an effective TDC inhibitor that targets both
human and bacterial decarboxylases. Alternatively, we are cur-
rently evaluating regulation of tdc gene expression to help avoid
the need for high levodopa dosing, thus minimizing its adverse
side effects.
Notably, a few Enterococcus strains that harbor the tdc gene are
marked as probiotics. The use of such strains as dietary supple-
ments should be recognized in case of PD patients. More gen-
erally, our data support the increasing interest in the impact that
gut microbiota metabolism may have on medical treatment and
diet.
Collectively, our data show that levodopa conversion by bac-
terial TDC in the small intestine should be considered as a sig-
niﬁcant explanatory factor for the increased levodopa/carbidopa
dosage regimen required in a subset of PD patients. Although the
data from PD patients are tentative due to small number of
samples, this study strongly suggests these bacteria or their
encoded tdc gene may potentially serve as a predictive biomarker
to stratify PD patients for efﬁcacy of levodopa treatment as
supported by the signiﬁcant (r= 0.66) correlation observed
between the relative abundance of bacterial tdc genes in stool
samples of patients and number of levodopa/carbidopa tablets
required to treat individual PD patients (Fig. 5). To overcome the
limitation of the small number of samples from PD patients in
this study, we are currently validating the development of such a
simple cost-effective novel biomarker for optimal dosage of
levodopa/carbidopa and to prevent side effects in a large long-
itudinal cohort of newly diagnosed PD patients, who are followed
over long periods of time.
Methods
Human fecal samples from patients with Parkinson’s disease. Fecal samples
from patients diagnosed with Parkinson’s disease (n= 10) on variable doses
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Fig. 6 Luminal and plasma levels of levodopa are compromised by higher abundance of tyrosine decarboxylase gene in the small intestine of rats. Scatter
plot of tdc gene abundance measured by qPCR in jejunal content of wild-type Groningen rats (n= 18) orally supplied with levodopa/carbidopa mixture
(4:1) versus a the dopamine: levodopa/carbidopa levels in the jejunal content, the levodopa/carbidopa levels in the jejunal content, b or the levodopa/
carbidopa levels in the plasma, ﬁtted with a linear regression model. Intake of levodopa/carbidopa was corrected by using carbidopa as an internal
standard. Pearson’s r correlation was used to determine signiﬁcant correlations between tdc abundance and jejunal dopamine levels (r= 0.78, R2= 0.61,
P value= 0.0001), jejunal levodopa/carbidopa levels (r=−0.68, R2= 0.46 P value= 0.021), or plasma levodopa/carbidopa levels (r=−0.57, R2= 0.33,
P value= 0.017). No levodopa/carbidopa, dopamine, or DOPAC were detected in the control group (n= 5). c Signiﬁcant difference in plasma levels of
levodopa/carbidopa orally supplied to rats after treatment with EFSWT (n= 10) or EFSΔTDC (n= 10). Signiﬁcance was tested using parametric unpaired T-
test (**p < 0.01)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08294-y
8 NATURE COMMUNICATIONS |          (2019) 10:310 | https://doi.org/10.1038/s41467-019-08294-y | www.nature.com/naturecommunications
from the Movement Disorder Center at Rush University Medical Center, Chicago,
Illinois, USA. Patients’ characteristics were published previously35 (more details are
provided in Supplementary Table 4). Solid fecal samples were collected in anae-
robic fecal bags and kept sealed in a cold environment until brought to the hospital
where they were immediately stored at −80 °C until analysis.
Rats. All animal procedures were approved by the Groningen University Com-
mittee of Animal experiments (approval number: AVD1050020184844), and were
performed in adherence to the NIH Guide for the Care and Use of Laboratory
Animals.
Twenty-ﬁve male wild-type Groningen rats (Groningen breed, male, age
18–24 weeks) housed 4–5 animals/cage had ad libitum access to water and food
(RMH-B, AB Diets; Woerden, the Netherlands) in a temperature (21 ± 1 °C) and
humidity-controlled room (45–60% relative humidity), with a 12 h light/dark cycle
(lights off at 1:00 p.m.). These outbred rats are very frequently used in behavioral
studies36 due to the high inter-individual variation (also in their microbiota
composition), thus resembling, to some extent, the human inter-individual
variation. On ten occasions over a period of three weeks, rats were taken from their
social housing cage between circadian times 6 and 16.5, and put in an individual
training cage (L ×W ×H= 25 × 25 × 40 cm) with a layer of their own sawdust
without food and water. Ten minutes after transfer to these cages, rats were offered
a drinking pipette in their cages with a 2.5 ml saccharine solution (1.5 g/L, 12476,
Sigma). Over the course of training, all rats learned to drink the saccharine solution
avidly. On the 11th occasion, the saccharine solution was used as vehicle for the
levodopa/carbidopa mixture (15/3.75 mg/kg), which all rats drank within 15 s.
Fifteen minutes after drinking the latter mixture (maximum bioavailability time
point of levodopa in blood as previously described22, the rats were anesthetized
with isoﬂurane and sacriﬁced. Blood was withdrawn by heart puncture and placed
in tubes pre-coated with 5 mM EDTA. The collected blood samples were
centrifuged at 1500× g for 10 min at 4 °C and the plasma was stored at −80 °C
prior to levodopa, dopamine, and DOPAC extraction. Luminal contents were
harvested from the entire rat jejunum by gentle pressing and were snap frozen in
liquid N2, stored at −80 °C until used for qPCR, and extraction of levodopa and its
metabolites. The jejunum was distinguished from ileum by length (the intestinal
tubes starting at 5 cm from stomach to cecum was divided into two; the proximal
part was considered jejunum) Oral administration (by drinking, with saccharine as
vehicle) of levodopa was corrected for by using carbidopa as an internal standard to
correct for intake. Further, ﬁve rats were used as control and were administered a
saccharine only solution (vehicle) to check for basal levels of levodopa, dopamine,
and DOPAC levels or background HPLC-peaks. Jejunal content of control rats was
used in ex vivo fermentation experiments (see incubation experiments of jejunal
content section).
Treatment with EFSWT and EFSΔTDC bacteria. Rats (n= 20) were treated orally
with 200 mg/kg body weight Rifaximin (R9904, Sigma) for ﬁve consecutive days as
previously shown29. Subsequently, the rats were treated orally with 1010–1011 CFU
wild type (n= 10) or Δtdc (n= 10) E. faecalis v583 cells (EFSWT and EFSΔTDC
respectively) for ﬁve other consecutive days. One day following the bacterial
treatment, the rats were orally supplied with levodopa/carbidopa mixture (4:1) as
described above.
Bacteria. Escherichia coli DH5a or BL21 were routinely grown aerobically in Luria-
Broth (LB) at 37 °C degrees with continuous agitation. Other strains listed in
Supplementary Table 6 were grown anaerobically (10% H2, 10% CO2, 80% N2) in a
Don Whitley Scientiﬁc DG250 Workstation (LA Biosystems, Waalwijk, The
Netherlands) at 37 °C in an enriched beef broth based on SHIME medium37
(Supplementary Table 7). Bacteria were inoculated from −80 °C stocks and grown
overnight. Before the experiment, cultures were diluted 1:100 in fresh medium
from overnight cultures. Levodopa (D9628, Sigma, The Netherlands), carbidopa
(C1335, Sigma), benserazide (B7283, Sigma), or methyldopa (857416, Sigma) were
supplemented during the lag or stationary phase depending on the experiment.
Growth was followed by measuring the optical density (OD) at 600 nM in a
spectrophotometer (UV1600PC, VWR International, Leuven, Belgium).
Cloning and heterologous gene expression. The human DOPA decarboxylase
gene cloned in pET15b was ordered from GenScript (Piscataway, USA) (Supple-
mentary Table 6). TDC-encoding genes from E. faecalis v583 (TDCEFS, accession:
EOT87933), E. faecium W54 (TDCEFM, accession: MH358385; PTDCEFM, acces-
sion: MH358384) were ampliﬁed using Phusion High-ﬁdelity DNA polymerase
and primers listed in Supplementary Table 8. All ampliﬁed genes were cloned in
pET15b, resulting in pSK18, pSK11, and pSK22, respectively (Supplementary
Table 6). Plasmids were maintained in E. coli DH5α and veriﬁed by Sanger
sequencing before transformation to E. coli BL21 (DE3). Overnight cultures were
diluted 1:50 in fresh LB medium with the appropriate antibiotic and grown to
OD600= 0.7–0.8. Protein translation was induced with 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG, 11411446001, Roche Diagnostics) and cultures were













































Fig. 7 Higher abundance of tyrosine decarboxylase can explain increased levodopa administration requirement in Parkinson’s disease patients. A model
representing two opposing situations, in which the proximal small intestine is colonized by low (left) or high abundance of tyrosine decarboxylase-encoding
bacteria. The latter could result from or lead to increased individual L-DOPA dosage intake
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and stored at −80 °C or directly used for protein isolation. Cell pellets were thawed
on ice and resuspended in 1/50th of buffer A (300 mM NaCl; 10 mM imidazole;
50 mM KPO4, pH 7.5) containing 0.2 mg/mL lysozyme (105281, Merck) and 2 µg/
mL DNAse (11284932001, Roche Diagnostics), and incubated for at least 10 min
on ice before sonication (10 cycles of 15 s with 30 s cooling at 8 microns amplitude)
using Soniprep-150 plus (Beun de Ronde, Abcoude, The Netherlands). Cell debris
were removed by centrifugation at 20,000 × g for 20 min at 4 °C. The 6 × his-tagged
proteins were puriﬁed using a nickel-nitrilotriacetic acid (Ni-NTA) agarose matrix
(30250, Qiagen). Cell-free extracts were loaded on 0.5 ml Ni-NTA matrixes and
incubated on a roller shaker for 2 h at 4 °C. The Ni-NTA matrix was washed three
times with 1.5 ml buffer B (300 mM NaCl; 20 mM imidazole; 50 mM KPO4, pH
7.5) before elution with buffer C (300 mM NaCl; 250 mM imidazole; 50 mM KPO4,
pH 7.5). Imidazole was removed from puriﬁed protein fractions using Amicon
Ultra centrifugal ﬁlters (UFC505024, Merck) and washed three times and recon-
stituted in buffer D (50 mM Tris-HCL; 300 mM NaCl; pH 7.5) for TDCEFS, and
TDCEFM, buffer E (100 mM KPO4; pH 7.4) for PTDCEFM and buffer F (100 mM
KPO4; 0.1 mM pyridoxal-5-phosphate; pH 7.4) for DDC. Protein concentrations
were measured spectrophotometrically (Nanodrop 2000, Isogen, De Meern, The
Netherlands) using the predicted extinction coefﬁcient and molecular weight from
ExPASy ProtParam tool (www.web.expasy.org/protparam/).
Enzyme kinetics and IC50 curves. Enzyme kinetics were performed in 200 mM
potassium acetate buffer containing 0.1 mM PLP (pyridoxal-5-phosphate, P9255,
Sigma, The Netherlands) and 10 nM of enzyme at pH 5 for TDCEFS and TDCEFM,
and pH 4.5 for PTDCEFM. Reactions were performed in triplicate using levodopa
substrate ranges from 0.5 to 12.5 mM and tyrosine substrate ranges from 0.25 to
2.5 mM. Michaelis–Menten kinetic curves were ﬁtted using GraphPad Prism 7. The
human dopa decarboxylase kinetic reactions were performed in 100 mM potassium
phosphate buffer at pH 7.4 containing 0.1 mM PLP and 10 nM enzyme con-
centrations with levodopa substrate ranges from 0.1 to 1.0 mM. Reactions were
stopped with 0.7% HClO4, ﬁltered and analyzed on the HPLC-ED-system descri-
bed below. For IC50 curves, the reaction was performed using levodopa as the
substrate at concentrations lower or equal to the Km of the decarboxylases (DDC,
0.1 mM; TDCEFS and TDCEFM, 1.0 mM; PTDCEFM, 0.5 mM) with 10 different
concentrations of carbidopa in triplicate (human dopa decarboxylase,
0.005–2.56 µM; bacterial TDCs, 2–1024 µM).
HPLC-ED analysis and sample preparation. A volume of 1 mL of ice-cold
methanol was added to 0.25 mL cell suspensions. Cells and protein precipitates
were removed by centrifugation at 20,000 × g for 10 min at 4 °C. Supernatant was
transferred to a new tube and the methanol fraction was evaporated in a Savant
speed-vacuum dryer (SPD131, Fisher Scientiﬁc, Landsmeer, The Netherlands) at
60 °C for 1 h 15 min. The aqueous fraction was reconstituted to 1 mL with 0.7%
HClO4. Samples were ﬁltered and injected into the HPLC system (Jasco AS2059
plus autosampler, Jasco Benelux, Utrecht, The Netherlands; Knauer K-1001 pump,
Separations, H. I. Ambacht, The Netherlands; Dionex ED40 electrochemical
detector, Dionex, Sunnyvale, USA, with a glassy carbon working electrode (DC
amperometry at 1.0 V or 0.8 V, with Ag/AgCl as reference electrode)). Samples
were analyzed on a C18 column (Kinetex 5 µM, C18 100 Å, 250 × 4.6 mm, Phe-
nomenex, Utrecht, The Netherlands) using a gradient of water/methanol with 0.1%
formic acid (0–10 min, 95−80% H2O; 10–20 min, 80–5% H2O; 20–23 min 5%
H2O; 23–31 min 95% H2O). Data recording and analysis were performed using
Chromeleon software (version 6.8 SR13).
Bioinformatics. TDCEFS (NCBI accession: EOT87933) was BLASTed against the
protein sequences from the NIH HMP data bank using search limits for Entrez
Query “43021[BioProject]”. All BLASTp hits were converted to a distance tree
using NCBI TreeView (Parameters: Fast Minimum Evolution; Max Seq Difference,
0.9; Distance, Grishin). The tree was exported in Newick format and visualized in
iTOL phylogentic display tool (http://itol.embl.de/). Whole genomes or contigs
containing the tdc cluster were extracted from NCBI and aligned using Mauve
multiple genome alignment tool (v 2.4.0, www.darlinglab.org/mauve/mauve.html).
Incubation experiments of jejunal content. Luminal contents from the jejunum
of wild-type Groningen rats (n= 5) were suspended in EBB (5% w/v) containing
1 mM levodopa and incubated for 24 h in an anaerobic chamber at 37 °C prior to
HPLC-ED analysis (DC amperometry at 0.8 V).
DNA extraction. DNA was extracted from fecal samples of Parkinson’s patients
and jejunal contents of rats using QIAGEN (Cat no. 51504) kit-based DNA iso-
lation38 with the following modiﬁcations: fecal samples were suspended in 1 mL
inhibitEX buffer (1:5 w/v) and transferred to screw-caped tubes containing 0.5 g of
0.1 mm and 3 mm glass beads. Samples were homogenized 3 × 30 sec with 1-
minute intervals on ice in a mini bead-beater (Biospec, Bartlesville, USA) three
times before proceeding according to manufacturer’s protocol (Isolation of DNA
from Stool for Pathogen Detection).
Quantiﬁcation of bacterial TDC. To identify bacterial species carrying the tdc
gene, a broad range of tdc genes from various bacterial genera were targeted as
previously described39 (Supplementary Fig. 5). Quantitative PCR (qPCR) of tdc
genes was performed on DNA extracted from each fecal sample of Parkinson’s
patients and rats’ jejunal content using primers (Dec5f and Dec3r) targeting a 350
bp region of the tdc gene. Primers targeting 16S rRNA gene for all bacteria (Eub338
and Eub518) were used as an internal control (Supplementary Table 8). All qPCR
experiments were performed in a Bio-Rad CFX96 RT-PCR system (Bio-Rad
Laboratories, Veenendaal, The Netherlands) with iQ SYBR Green Supermix (170-
8882, Bio-Rad) in triplicate on 20 ng DNA in 10 µL reactions using the manu-
facturer’s protocol. qPCR was performed using the following parameters: 3 min at
95 °C; 15 sec at 95 °C, 1 min at 58 °C, 40 cycles. A melting curve was determined at
the end of each run to verify the speciﬁcity of the PCR amplicons. Data analysis
was performed using the BioRad software. Ct[DEC] values were corrected with the
internal control (Ct[16 s]) and linearized using 2^-(Ct[DEC]-Ct[16 s]) based on
the 2^-ΔΔCt method40.
Jejunal and plasma extraction of levodopa metabolites. Levodopa, dopamine,
and DOPAC were extracted from each luminal jejunal content and plasma samples
of rats using activated alumina powder (199966, Sigma) as previously described41
with a few modiﬁcations. A volume of 50–200 µl blood plasma was used with 1 µM
DHBA (3, 4-dihydroxybenzylamine hydrobromide, 858781, Sigma) as an internal
standard. For jejunal luminal content samples, an equal amount of water was added
(w/v), and suspensions were vigorously mixed using a vortex. Suspensions were
subsequently centrifuged at 20,000× g for 10 min at 4°C. A volume of 50–200 µL of
supernatant was used for extraction. Samples were adjusted to pH 8.6 with
200–800 µl TE buffer (2.5% EDTA; 1.5 M Tris/HCl pH 8.6) and 5–10 mg of alu-
mina was added. Suspensions were mixed on a roller shaker at room temperature
for 15 min and were thereafter centrifuged for 30 s at 20,000× g and washed twice
with 1 mL of H2O by aspiration. Levodopa and its metabolites were eluted using
0.7% HClO4 and ﬁltered before injection into the HPLC-ED-system as described
above (DC amperometry at 0.8 V).
Statistical analysis and (non)linear regression models. All statistical tests and
(non)linear regression models were performed using GraphPad Prism 7. Statistical
tests performed are unpaired T-tests, 2-way-ANOVA followed by a Fisher’s LSD
test. Speciﬁc tests and signiﬁcance are indicated in the ﬁgure legends.
Data availability
The authors declare that all the data supporting the ﬁndings of this study are
available within the paper and its supplementary information ﬁles. The sequences
of the TDC genes from E. faecium W54 TDCEFM and PTDCEFM have been
deposited under NCBI accession numbers MH358385, MH358384, respectively.
The gene sequence of E. faecalis v583 TDCEFS was already available under NCBI
accession number EOT87933.
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